| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Molecular Targets, and Chemical Biology |
1 Department of Medicine and Bioregulatory Sciences, The University of Tokushima Graduate School of Health Biosciences; 2 Division of Transfusion Medicine, Tokushima University Hospital, Tokushima, Japan; and 3 Genome Antibody Research Department, 4 Pharmaceutical Research Department III, and 5 Product Planning Department, Chugai Pharmaceutical Co. Ltd., Tokyo, Japan
Requests for reprints: Shuji Ozaki, Department of Medicine and Bioregulatory Sciences, The University of Tokushima Graduate School of Health Biosciences, 3-18-15 Kuramoto, Tokushima 770-8503, Japan. Phone: 81-88-633-7120; Fax: 81-88-633-7121; E-mail: ozakishu{at}clin.med.tokushima-u.ac.jp.
Cross-linked human leukocyte antigen (HLA) class I molecules have been shown to mediate cell death in neoplastic lymphoid cells. However, clinical application of an anti-HLA class I antibody is limited by possible side effects due to widespread expression of HLA class I molecules in normal tissues. To reduce the unwanted Fc-mediated functions of the therapeutic antibody, we have developed a recombinant single-chain Fv diabody (2D7-DB) specific to the
2 domain of HLA-A. Here, we show that 2D7-DB specifically induces multiple myeloma cell death in the bone marrow environment. Both multiple myeloma cell lines and primary multiple myeloma cells expressed HLA-A at higher levels than normal myeloid cells, lymphocytes, or hematopoietic stem cells. 2D7-DB rapidly induced Rho activation and robust actin aggregation that led to caspase-independent death in multiple myeloma cells. This cell death was completely blocked by Rho GTPase inhibitors, suggesting that Rho-induced actin aggregation is crucial for mediating multiple myeloma cell death. Conversely, 2D7-DB neither triggered Rho-mediated actin aggregation nor induced cell death in normal bone marrow cells despite the expression of HLA-A. Treatment with IFNs, melphalan, or bortezomib enhanced multiple myeloma cell death induced by 2D7-DB. Furthermore, administration of 2D7-DB resulted in significant tumor regression in a xenograft model of human multiple myeloma. These results indicate that 2D7-DB acts on multiple myeloma cells differently from other bone marrow cells and thus provide the basis for a novel HLA class Itargeting therapy against multiple myeloma. [Cancer Res 2007;67(3):118492]
This article has been cited by other articles:
![]() |
E. Spanoudakis, M. Hu, K. Naresh, E. Terpos, V. Melo, A. Reid, I. Kotsianidis, S. Abdalla, A. Rahemtulla, and A. Karadimitris Regulation of multiple myeloma survival and progression by CD1d Blood, March 12, 2009; 113(11): 2498 - 2507. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Yang, Y. Cao, S. Hong, H. Li, J. Qian, L. W. Kwak, and Q. Yi Human-Like Mouse Models for Testing the Efficacy and Safety of Anti-{beta}2-Microglobulin Monoclonal Antibodies to Treat Myeloma Clin. Cancer Res., February 1, 2009; 15(3): 951 - 959. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-T. Tai, M. Dillon, W. Song, M. Leiba, X.-F. Li, P. Burger, A. I. Lee, K. Podar, T. Hideshima, A. G. Rice, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu Blood, August 15, 2008; 112(4): 1329 - 1337. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Jalili, S. Ozaki, N. Kimura, M. Abe, and T. Matsumoto Multi-Drug Resistant Leukemic Cells Highly Express HLA Class I Molecules and Single-Chain Fv Diabody Specific to HLA-A Overcomes Drug Resistance in These Cells. Blood (ASH Annual Meeting Abstracts), November 16, 2007; 110(11): 2376 - 2376. [Abstract] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |